Side effects of Pazopanib in renal cell carcinoma.

This article provides practical guidance for oncology nurses on the recognition and management of potential side effects associated with the tyrosine kinase inhibitor pazopanib for treating adults with advanced renal cell carcinoma (aRCC). This guidance was developed by a panel of six oncology nurses experienced in the use of pazopanib therapy for patients with aRCC. Regular monitoring, early identification and prompt intervention are essential for optimal management of any therapy-associated side effects, along with education to empower patients to take control of their symptoms. While pazopanib shows an acceptable and manageable safety profile, it is important that oncology teams are aware of potential side effects and have strategies in place should they occur. These measures could minimise the need for dose modifications, allowing patients to gain the maximum benefit from treatment.